Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Bacteriology|August 5, 2004
Defined inactive FecA derivatives mutated in functional domains of the outer membrane transport and signaling protein of Escherichia coli K-12Annette Sauter, Volkmar Braun
Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine|May 24, 2006
Gene regulation by transmembrane signalingVolkmar Braun, Susanne Mahren, Annette Sauter
Biometals : an International Journal on the Role of Metal Ions in Biology, Biochemistry, and Medicine|December 8, 2005
Gene regulation by transmembrane signalingVolkmar Braun, Susanne Mahren, Annette Sauter
Journal of Bacteriology|September 18, 2003
In vivo evidence for TonB dimerizationAnnette Sauter, S Peter Howard, Volkmar Braun
Clinical Pharmacokinetics|April 11, 2019
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I TrialsKatrijn Bogman, Jochen Brumm, Carsten Hofmann, et al.
Multiple Sclerosis and Related Disorders|January 22, 2021
COVID-19 in ocrelizumab-treated people with multiple sclerosisRichard Hughes, Louise Whitley, Kocho Fitovski, et al.
Journal of Neurology|October 31, 2023
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extensionLudwig Kappos, Anthony Traboulsee, David K B Li, et al.
Neurology|September 6, 2019
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosisFrederik Barkhof, Ludwig Kappos, Jerry S Wolinsky, et al.
The Lancet. Neurology|November 1, 2020
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trialJerry S Wolinsky, Douglas L Arnold, Bruno Brochet, et al.
Ebiomedicine|June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsAmit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
Pageof 2